Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 97 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $79,695 | -93.7% | 6,597 | -91.5% | 0.00% | -85.7% |
| Q1 2024 | $1,264,800 | +399.7% | 77,786 | +109.6% | 0.01% | +250.0% |
| Q4 2023 | $253,104 | +27.1% | 37,112 | +1.5% | 0.00% | +100.0% |
| Q3 2023 | $199,214 | -78.8% | 36,553 | -73.6% | 0.00% | -83.3% |
| Q2 2023 | $940,741 | +229.3% | 138,548 | +143.0% | 0.01% | +200.0% |
| Q1 2023 | $285,696 | +49.5% | 57,025 | +45.6% | 0.00% | +100.0% |
| Q4 2022 | $191,096 | +32.7% | 39,159 | +291.6% | 0.00% | 0.0% |
| Q3 2022 | $144,000 | -10.0% | 10,000 | -5.1% | 0.00% | 0.0% |
| Q2 2022 | $160,000 | +5.3% | 10,542 | -17.5% | 0.00% | 0.0% |
| Q1 2022 | $152,000 | -64.2% | 12,783 | -14.1% | 0.00% | -80.0% |
| Q3 2021 | $425,000 | +60.4% | 14,884 | +177.9% | 0.01% | +25.0% |
| Q4 2020 | $265,000 | +2108.3% | 5,356 | +930.0% | 0.00% | – |
| Q2 2019 | $12,000 | -78.2% | 520 | -75.0% | 0.00% | -100.0% |
| Q3 2018 | $55,000 | – | 2,082 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
| Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
| MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
| Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
| Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
| ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
| Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
| Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
| Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
| Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |